ICLR vs SNY
ICON Public Limited Company vs Sanofi — AI-powered side-by-side comparison
ICLR
ICON Public Limited Company
68
Buy
VS
| Metric | ICLR | SNY |
|---|
| AI Score |
68
|
68
|
| Price |
$163.01
|
$43.70
|
| P/E Ratio |
39.04×
|
23.11×
|
| ROE |
2.5%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
21.8%
|
72.8%
|
| Debt / Equity |
0.37×
|
0.34×
|
| Dividend Yield |
0.0%
|
5.5%
|
| RSI (14) |
55.0
|
56.9
|
| Beta |
1.203
|
0.278
|
| Expected Upside |
+17.5%
|
+3.4%
|
AI Committee View
Current Innellis committee reasoning for ICLR versus SNY.
The committee scores are tied.
ICLR and SNY both score 68/100.
ICLR Committee View
50% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.4% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth